Follicular development in a 7-day versus 4-day hormone-free interval with an oral contraceptive containing 20 mcg ethinyl estradiol and 1 mg norethindrone acetate

Contraception ◽  
2009 ◽  
Vol 79 (3) ◽  
pp. 182-188 ◽  
Author(s):  
Radhika D. Rible ◽  
DeShawn Taylor ◽  
Melissa L. Wilson ◽  
Frank Z. Stanczyk ◽  
Daniel R. Mishell
Keyword(s):  
Oral Contraceptive ◽  
Ethinyl Estradiol ◽  
Follicular Development ◽  
Free Interval ◽  
Norethindrone Acetate

Use of a low-dose oral contraceptive containing norethindrone acetate and ethinyl estradiol in the treatment of moderate acne vulgaris

2001 ◽  
Vol 1 (3) ◽  
pp. 123-131 ◽  
Author(s):  
J. Michael Maloney ◽  
Deborah I. Arbit ◽  
Mary Flack ◽  
Constance McLaughlin-Miley ◽  
Cynthia Sevilla ◽  
...  
Keyword(s):  
Oral Contraceptive ◽  
Low Dose ◽  
Ethinyl Estradiol ◽  
Acne Vulgaris ◽  
Dose Oral ◽  
Dose Oral Contraceptive ◽  
Norethindrone Acetate

scholarly journals Safety and Efficacy of Levonorgestrel 0.10 mg and Ethinyl Estradiol 0.02 mg plus Ethinyl Estradiol 0.01 mg in an Extended-Cycle Oral Contraceptive Regimen

2010 ◽  
Vol 2 ◽  
pp. CMT.S4661
Author(s):  
Radhika Rible ◽  
Ram Parvataneni ◽  
Angela Chen
Keyword(s):  
Oral Contraceptive ◽  
Ethinyl Estradiol ◽  
Hormonal Contraception ◽  
Pivotal Trial ◽  
Combined Oral Contraceptive ◽  
Free Interval ◽  
Effective Option ◽  
Effective Contraception ◽  
Combined Hormonal Contraception ◽  
Extended Cycle

Extended-cycle combined hormonal contraception has become a common practice among women seeking effective contraception and menstrual regulation. Extended cycle regimens have the benefit of decreasing scheduled bleeding as compared to traditional combined oral contraceptive (COC) regimens containing 21 days of hormones followed by a 7-day hormone-free interval (HFI) by reducing the frequency of the HFI. The newest FDA approved product in this family of contraceptive regimens is a 91-day COC regimen containing 0.02 mg ethinyl estradiol (EE) and 0.1 mg levonorgestrel (LNG) for 84 days followed by a 7-day interval with 0.01 mg EE. This regimen has been evaluated in one pivotal trial and demonstrated to have efficacy and a side effect profile similar to the other currently available FDA approved 91-day extended-cycle regimens. This is the first 91-day regimen formulated with 0.02 mg EE and offers women an effective option for contraception and menstrual cycle control.

scholarly journals Unilateral Erythema Nodosum following Norethindrone Acetate, Ethinyl Estradiol, and Ferrous Fumarate Combination Therapy

2016 ◽  
Vol 2016 ◽  
pp. 1-3
Author(s):  
Michelle S. Min ◽  
Rob Fischer ◽  
John B. Fournier
Keyword(s):  
Oral Contraceptive ◽  
Combination Therapy ◽  
Oral Contraceptives ◽  
Erythema Nodosum ◽  
Ethinyl Estradiol ◽  
Oral Contraceptive Pills ◽  
Ferrous Fumarate ◽  
Contraceptive Pills ◽  
Secondary Causes ◽  
Norethindrone Acetate

Erythema nodosum is a septal panniculitis that typically presents as symmetric, tender nodules on the anterior aspects of bilateral lower extremities. Nearly half of cases are due to secondary causes, with oral contraceptive pills being the leading pharmaceutical cause. However, to our knowledge, there has yet to be a published association with norethindrone acetate, ethinyl estradiol, and ferrous fumarate. We report our experience with a 30-year-old woman who developed unilateral tender nodules within a month of starting 1 mg norethindrone acetate and 20 mcg ethinyl estradiol daily. Of note, she had previously taken oral contraceptives with the same estrogen agent but different progesterone, without problems. We conclude that systemically triggered erythema nodosum can present with lesions localized to one extremity. When a patient presents with tender, firm nodules, clinicians should consider the possibility of erythema nodosum and its triggers, such as oral contraceptives. Additionally, should a patient on hormonal therapy develop erythema nodosum, changing the progesterone agent may allow the patient to continue similar therapy without developing symptoms.

Norethindrone Acetate 1.0 Milligram and Ethinyl Estradiol 10 Micrograms as an Ultra Low-Dose Oral Contraceptive

2013 ◽  
Vol 122 (3) ◽  
pp. 601-607 ◽  
Author(s):  
David F. Archer ◽  
Steven T. Nakajima ◽  
Allan T. Sawyer ◽  
Jeffrey Wentworth ◽  
Suzanne Trupin ◽  
...  
Keyword(s):  
Oral Contraceptive ◽  
Low Dose ◽  
Ethinyl Estradiol ◽  
Dose Oral ◽  
Dose Oral Contraceptive ◽  
Norethindrone Acetate
Sign in / Sign up

Export Citation Format

Share Document